Cobblestone Capital Advisors LLC NY Has $242,000 Holdings in Medtronic plc (NYSE:MDT)

Cobblestone Capital Advisors LLC NY lowered its position in shares of Medtronic plc (NYSE:MDT) by 8.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,027 shares of the medical technology company’s stock after selling 262 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in Medtronic were worth $242,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Principal Securities Inc. raised its position in Medtronic by 6.7% during the third quarter. Principal Securities Inc. now owns 47,656 shares of the medical technology company’s stock valued at $4,290,000 after buying an additional 2,981 shares during the period. Hills Bank & Trust Co acquired a new position in shares of Medtronic in the 3rd quarter valued at about $108,000. Capital Advisors Inc. OK increased its holdings in shares of Medtronic by 3.8% in the 3rd quarter. Capital Advisors Inc. OK now owns 316,031 shares of the medical technology company’s stock valued at $28,452,000 after purchasing an additional 11,708 shares during the period. Weatherly Asset Management L. P. acquired a new position in shares of Medtronic in the 3rd quarter valued at about $231,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Medtronic by 13.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 38,280 shares of the medical technology company’s stock valued at $3,446,000 after purchasing an additional 4,490 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MDT shares. UBS Group upped their price objective on shares of Medtronic from $85.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. Truist Financial dropped their price target on shares of Medtronic from $93.00 to $89.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Barclays upped their price target on shares of Medtronic from $105.00 to $109.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 26th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Medtronic in a research report on Wednesday, February 19th. Finally, JPMorgan Chase & Co. dropped their target price on Medtronic from $99.00 to $96.00 and set a “neutral” rating on the stock in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Hold” and a consensus target price of $95.00.

Medtronic Trading Up 1.4 %

Shares of MDT stock opened at $92.00 on Friday. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $93.08. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $87.08 and its two-hundred day moving average is $87.46. The company has a market cap of $117.97 billion, a PE ratio of 27.96, a price-to-earnings-growth ratio of 2.22 and a beta of 0.84.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.03. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The business had revenue of $8.29 billion for the quarter, compared to analyst estimates of $8.33 billion. Equities analysts predict that Medtronic plc will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Friday, December 27th were given a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 3.04%. The ex-dividend date was Friday, December 27th. Medtronic’s dividend payout ratio is currently 85.11%.

Insider Activity

In other Medtronic news, EVP Brett A. Wall sold 12,437 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $90.00, for a total value of $1,119,330.00. Following the sale, the executive vice president now owns 40,979 shares of the company’s stock, valued at $3,688,110. This trade represents a 23.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.